AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CLINUVEL PHARMACEUTICALS LTD

8.130

-0.230-2.75%

Volume:129.80K

Turnover:1.06M

Market Cap:408.13M

PE:12.17

High:8.350

Open:8.250

Low:8.030

Close:8.360

52wk High:13.399

52wk Low:7.930

Shares:50.20M

Float Shares:41.32M

Volume Ratio:0.85

T/O Rate:0.31%

Dividend:0.05

Dividend Rate:0.62%

EPS(TTM):0.668

EPS(LYR):0.668

ROE:13.21%

ROA:8.94%

PB:1.50

PE(LYR):12.17

Loading ...

Overview Company News Filings

Concept

Pharmaceutical Companies-0.31%

Capital Flow

Inflow:

Outflow:

News

Clinuvel Pharmaceuticals Completes Development of Proprietary Drug Delivery Device

MT Newswires Live

Spotlight for Clinuvel Turning to Vitiligo Trial Readout

Clinuvel Pharmaceuticals (ASX:CUV) Shares Undervalued Or Warning On Single Drug Risk?

Simply Wall St.

Morgans Financial Downgrades Clinuvel Pharmaceuticals to Hold from Speculative Buy; Price Target is AU$10

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/stock/CUV.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CUV.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","market":"AU","secType":"STK","nameCN":"CLINUVEL PHARMACEUTICALS LTD","latestPrice":8.13,"timestamp":1789539120000,"preClose":8.36,"halted":0,"volume":129804,"delay":0,"changeRate":-0.02751196172248788,"nameEN":"CLINUVEL PHARMACEUTICALS LTD","floatShares":41318955,"shares":50200740,"eps":0.667999,"marketStatus":"Not Yet Opened","change":-0.23,"latestTime":"09-16 16:12:00 AEST","open":8.25,"high":8.35,"low":8.03,"amount":1055919,"amplitude":0.038278,"askPrice":8.24,"askSize":1500,"bidPrice":8.06,"bidSize":345,"shortable":3,"etf":0,"ttmEps":0.667999,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":8.36,"dividendRate":0.00615,"openAndCloseTimeList":[[1789516800000,1789538400000]],"volumeRatio":0.8467484686588779,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CUV.AU","preClose":8.36,"auctionPrice":8.13,"auctionVolume":18589,"auction":3,"marketStatus":"盘后竞价","timestamp":1789539003872}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","floatShares":41318955,"roa":"8.94%","roe":"13.21%","lyrEps":0.667999,"volumeRatio":0.8467484686588779,"shares":50200740,"dividePrice":0.05,"high":8.35,"amplitude":0.038278,"preClose":8.36,"low":8.03,"week52Low":7.93,"pbRate":"1.50","psRate":"4.34","week52High":13.399,"institutionHeld":0,"latestPrice":8.13,"committee":-0.626016,"eps":0.667999,"divideRate":0.00615,"volume":129804,"delay":0,"ttmEps":0.667999,"open":8.25,"prevYearClose":12.385,"prevWeekClose":8.04,"prevMonthClose":7.972,"prevQuarterClose":10.219,"fiveDayClose":8.16,"twentyDayClose":10.338,"sixtyDayClose":10.139,"dividendPayoutRate":0.07372445631899688,"dividendFrequency":"A","dividendGrowthYears":6,"dividendGrowthRate":0,"fiveYearAvgDividendRate":0.0033959070154716284},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CUV.AU\",params:#limit:5,,,undefined,":[{"date":"2026-09-03","symbol":"CUV.AU","amount":0.05,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-09-04","defaultRemindTime":1788393600000,"name":"CLINUVEL PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-18","payableDate":"2026-09-04","currency":"AUD","dateTimestamp":1788357600000,"payDate":"2026-09-18"},{"date":"2026-08-27","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787788800000,"name":null,"time":"","dateTimestamp":1787752800000,"actualEps":null},{"date":"2026-02-26","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1772060400000,"name":null,"time":"","dateTimestamp":1772024400000,"actualEps":null},{"date":"2025-09-04","symbol":"CUV.AU","amount":0.05,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-05","defaultRemindTime":1756944000000,"name":"CLINUVEL PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-05","currency":"AUD","dateTimestamp":1756908000000,"payDate":"2025-09-19"},{"date":"2025-08-28","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756339200000,"name":null,"time":"","dateTimestamp":1756303200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CUV.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-03","recordDate":"2020-09-04","paymentDate":"2020-09-18","value":0.025,"currency":"AUD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-17","value":0.025,"currency":"AUD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-09-21","value":0.04,"currency":"AUD"},{"executeDate":"2023-09-05","recordDate":"2023-09-06","paymentDate":"2023-09-20","value":0.05,"currency":"AUD"},{"executeDate":"2024-09-05","recordDate":"2024-09-06","paymentDate":"2024-09-20","value":0.05,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CUV.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665334536","title":"Clinuvel Pharmaceuticals Completes Development of Proprietary Drug Delivery Device","url":"https://stock-news.laohu8.com/highlight/detail?id=2665334536","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665334536?lang=en_us&edition=fundamental","pubTime":"2026-09-08 08:43","pubTimestamp":1788828205,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  completed the development of a proprietary single-use device for subcutaneous drug delivery aimed at both hospital use and self-administration, according to a Tuesday filing with the Australian bourse.The Zerokin device will be used to administer controlled-release formulations developed at the company's research, development and innovation center in Singapore, per the filing.Since it is intended as a Class 2 device, Zerokin will require registration for human use with the US Food and Drug Administration, and an application for CE marking under European Union regulations, the company said.It added that the global market for self-administered devices is forecast to grow to $40.5 billion by 2030 from $27.1 billion currently.Clinuvel Pharmaceuticals shares fell past 1% in recent Tuesday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663040960","title":"Spotlight for Clinuvel Turning to Vitiligo Trial Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2663040960","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663040960?lang=en_us&edition=fundamental","pubTime":"2026-08-31 07:01","pubTimestamp":1788130860,"startTime":"0","endTime":"0","summary":"2300 GMT - The spotlight for Clinuvel Pharmaceuticals is increasingly turning to the readout of the CUV105 trial, says Jefferies. It is due by the end of December. Clinuvel is currently involved in a Phase 3 clinical trial of afamelanotide as a potential treatment for vitiligo, which affects some 0.75% of the U.S. population. Current treatment options are suboptimal, analyst David Stanton says. Vitiligo is a repigmentation disease with a large total addressable market of up to US$570 million in the first two years of entry to the market. \"Given Phase 2 trial results, we believe afamelanotide may eventually offer a more definitive, full-body solution than current standards of care in vitiligo,\" says Jefferies, which has a buy call on Clinuvel.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","CUV.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663019945","title":"Clinuvel Pharmaceuticals (ASX:CUV) Shares Undervalued Or Warning On Single Drug Risk?","url":"https://stock-news.laohu8.com/highlight/detail?id=2663019945","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663019945?lang=en_us&edition=fundamental","pubTime":"2026-08-29 06:23","pubTimestamp":1787955839,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals closed at A$8.47 after a weak few months for the stock, with the share price down over the past week, month and quarter. Yet the latest full year numbers tell a calmer story. The company delivered around A$94.0m in trailing twelve month revenue with a net profit margin near 36%. That kind of profitability is unusual in biotech and underpins a trailing P/E of 12.6x that sits well below peers.\nFor long term holders, the key point is that this remains a highly...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-shares-undervalued-or-warnin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-shares-undervalued-or-warnin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK7067","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662064690","title":"Morgans Financial Downgrades Clinuvel Pharmaceuticals to Hold from Speculative Buy; Price Target is AU$10","url":"https://stock-news.laohu8.com/highlight/detail?id=2662064690","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662064690?lang=en_us&edition=fundamental","pubTime":"2026-08-28 18:43","pubTimestamp":1787913835,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) has an average rating of overweight and mean price target of AU$19.62, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":23,"pageCount":1,"totalSize":89,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CUV.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"Pharmaceutical Companies","id":"package_au_concept_yyswg","bkCode":"BK7508","changeRate":-0.003125}]}}